Key Investor Signals
Generated cosmetic sales to support device research
Regemed’s natural-cosmetics line generates sales that help co-finance its scientific and technological development, linking an existing skincare business with the device programme.
Joined the 2024 CRAASH Barcelona accelerator
Regemed was one of six teams selected for the 2024 health-innovation accelerator run by Biocat and CIMIT, receiving commercialisation training and expert mentoring.
Won a Catalan Demo Day pitch place at 4YFN
A jury selected Regemed among six of 20 projects at Spain’s Programa Primer Demo Day in December 2023 to pitch at the Catalan government’s 4YFN 2024 stand.
Team
Aleix Cuenca Pellejero
Co-founder
- Brings more than eight years of medical and scientific affairs experience across the medical and aesthetic sectors.
- Studied biology at the University of Barcelona and specialised in cosmetic formulation, clinical trials and medical affairs.
- Started a doctorate in medicine at the Autonomous University of Barcelona in 2023, focused on skin regeneration and tissue repair.
Olau Cantero Colomer
Co-founder
- Studied a combined business administration and law degree at the Autonomous University of Barcelona.
- Has pursued entrepreneurship since launching his first venture in 2021, before going on to co-found Regemed.
- Took Regemed through startup acceleration programmes including Biocat’s CRAASH Barcelona alongside co-founder Aleix Cuenca.
Product
Regemed’s device is being developed to process autologous material into a personalised topical formulation. Its approach combines automated preparation with gels, creams or ointments, initially for aesthetic medicine and supported by recurring consumables.
Automated sample preparation
The device is designed to process a patient’s own tissue within minutes. Automated preparation aims to standardise the treatment-making workflow while retaining biological material specific to each patient.
Skin-applied formulations
The processed material is formulated as gels, creams or ointments for application to the skin. The initial focus is aesthetic treatment; the formulation approach supports personalised topical delivery.
Device and consumable platform
The platform combines a medical device with recurring consumables for treatment preparation. This architecture is intended to support repeated use in clinical practice as individual treatments are prepared.
Market Overview
Clinician-operated equipment and consumables support personalised regenerative skin care. The adjacent platelet-rich plasma market already supplies hospitals and specialist clinics; in aesthetics, these products compete with fillers, skin-tightening devices and other rejuvenation treatments.
Aesthetic clinicians purchase preparation systems to deliver patient-paid procedures, with repeat treatments supporting demand for consumables. The commercial opportunity centres on convenient, reproducible preparation and clinician training. Dermatology and aesthetic clinics form a distinct segment within the broader blood-processing market.
Estimated worldwide PRP market revenue in 2025, spanning clinical applications beyond aesthetics.
Estimated procedures performed worldwide by plastic surgeons in 2024, according to ISAPS.
ISAPS estimated the global plastic-surgeon workforce in its survey of procedures performed in 2024.
Estimated share of global PRP revenue generated by the hospital end-use segment in 2025.
Comparable Outcomes
Harvest Technologies
Harvest developed point-of-care devices and kits that concentrate a patient’s own platelets or bone-marrow cells for tissue-healing procedures. Terumo acquired all shares in April 2011 for $70 million at closing, with up to $35 million in separate milestone payments scheduled for 2012–2015.
Interested in More Startups Like Regemed?
Get a curated pipeline of healthcare and life sciences startups aligned with your investment thesis.
Sources
This profile was built from public company materials, ecosystem sources, market references, and professional profiles.